Living With CML

Due to the increased use of tyrosine kinase inhibitors (TKIs) to treat chronic myelogenous leukemia, patient costs have soared. Financial navigators can help.

As part of our coverage of the 2018 American Society of Hematology (ASH) annual meeting in San Diego, Jan Geissler, a patient advocate and director of the European Patients Academy on Therapeutic Innovation, joined Patient Power to share his perspective on the latest news in chronic myeloid leukemia (CML).